33rd ESMO Congress in Stockholm, 12-16 Sept...( LUGANO Switzerland September 5 /-...)

LUGANO, Switzerland, September 5 /PRNewswire/ -- The 33rd ESMO Congress in Stockholm, the premier European congress in Oncology, serves as a meeting place for medical oncologists, as well as a focal point to exchange ideas with colleagues from other disciplines.

The Congress Centre will be the venue for interdisciplinary interaction, a teaching ground, and a place to discuss critical issues for European oncology such as cancer research in Europe, the training of young oncologists and better integration of medical oncology with other specialties and patient advocacy groups.

Highlights of Congress Program:

Please respect individual embargo dates/times

Access to drugs

European disparities in access to cancer drugs

(Embargoed until Monday, 15 September 2008, 12:30 CEST)

New research has highlighted stark disparities in access to the latest cancer drugs across European Union nations. Dr. Nils Wilking from the Karolinska Institute in Stockholm gathered data on the sales of newer drugs per inhabitant of each country provided by pharmaceutical industry consultants IMS Health. His group's focus was on the uptake of newer 'targeted' drugs over the past 10 years in 27 countries.

Lung Cancer

Significant benefits in non-small-cell lung cancer from customising

treatment

(Embargoed until Saturday 13 September 2008, 12:45 CEST)

Lung cancer patients whose tumours carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report. Investigators from the Spanish Lung Cancer Group conducted the largest-ever study to examine the benefits of customising lung cancer treatment based on mutations in the epidermal growth factor receptor (EGFR) gene.

Phase II trial of pazopanib before surgery in early lung cancer

(Embargoed until Monday, 15 September 2008, 10:45 CEST)

Pazop
'/>"/>